Affinity Asset Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Affinity Asset Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-29,105	Closed	-$2.97M	–	100
2023 Q2	$2.97M	Buy	+29,105	New	+$2.75M	1.04%	31

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Affinity Asset Advisors's RETA Position: Q3 2023 in Review

Affinity Asset Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 29,105 shares — an estimated $2.97M sold.

Affinity Asset Advisors first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $2.97M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Affinity Asset Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Affinity Asset Advisors sold 29,105 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.97M.
Affinity Asset Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Affinity Asset Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.97M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.